CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present at four upcoming Investor Conferences.  2018 RBC Capital Markets Global Healthcare Conference Date: Thursday, February 22, 2018 Presentation: 8:00-8:25 AM ETWebcast available under Investor Relations tab at CRISPRTx.com Barclays Global Healthcare Conference Date: Tuesday, March 13, 2018 Presentation: 3:20-3:45 PM ET  Guggenheim Conference on Disruptive Technologies in Immuno-Oncology Date: March 27th, 2018  17th Annual Needham Healthcare Conference Date: March 28th, 2018Presentation: 3:30 PM ET

About CRISPR Therapeutics CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com. MEDIA CONTACT: Jennifer Paganelli WCG on behalf of CRISPR +1 347-658-8290 [email protected] INVESTOR CONTACT: Chris Erdman +1 617.307.7227 [email protected]Chris Brinzey Westwicke Partners for CRISPR +1 339-970-2843 [email protected] 

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• FIA Celebrates Over Ninety Years of Supporting Motor Sport in the United States at the INDYCAR Freedom 250 Grand Prix of Washington D.C.
• AI Memecoin Trading 2026: Why Automated Agents Are Becoming the Future of Meme Markets